 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 08/22/2003 | | | | Alzheimer's Disease Rising Prevalence Will Challenge Health Care System
topic: R&D: Alzheimer's Disease Treatments
August 22, 2003: The challenges that Alzheimer's disease (AD) poses for health care systems as the baby-boom generation ages have been identified in expert reports and testimony before Congress. AD is the leading cause of dementia in the elderly, afflicting an estimated 4 million people in the United States alone. |
| 08/21/2003 | | | | Nymox Reports Positive NXC-4720 E. Coli Product Data
topic: R&D: E coli and Other Antibacterial Treatments
August 21, 2003: Nymox Pharmaceutical Corporation announced today that NXC-4720, its new product for E. coli O157:H7 meat contamination, has reached significant milestones in product development. The product has been validated in further independent tests. The Company is involved in ongoing further validation studies. |
| 08/20/2003 | | | | Nymox Reports Positive Data on AlzheimAlert™ Product
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
August 20, 2003: Nymox Pharmaceutical Corporation announced today that further recent studies have shown that the Company's AlzheimAlert™ urine test is an accurate diagnostic aid for Alzheimer's disease (AD). |
| 08/19/2003 | | | | Nymox Records Positive Interim Results in Phase I Testing of NX-1207 Prostate Drug
topic: R&D: BPH (enlarged prostate) Treatments
August 19, 2003: Nymox Pharmaceutical Corporation announced today interim analysis of initial Phase I human safety data for NX-1207, the Company's investigational new drug for benign prostatic hyperplasia (BPH). Initial BPH patients treated with NX-1207 overall have not shown clinically significant toxic effects from the drug. |
| 08/13/2003 | | | | Nymox Reports Second Quarter Results
topic: Financial
August 13, 2003: Nymox Pharmaceutical Corporation announced today its financial results for the second quarter of 2003. |
| 08/06/2003 | | | | Nymox Announces E. Coli Collaboration for Research with Health Canada
topic: R&D: E coli and Other Antibacterial Treatments
August 6, 2003: Nymox Pharmaceutical Corporation announced today a research collaboration with Health Canada's Laboratory for Foodborne Zoonoses in Guelph, Ontario for the research and development of novel animal and related treatments for E. coli 0157:H7, the deadly bacteria implicated in contamination of meat products and of drinking water supplies. |
| 07/24/2003 | | | | New Survey Results Show That Few Young Women Smokers Able to Quit
topic: Tobacco Exposure Tests
July 24, 2003: The results of two surveys released by the American Legacy Foundation show that 65% of young women smokers want to quit but only 3% succeed. Nymox believes that its NicAlert™ product can be a valuable aid to any smoking cessation program by providing a quick, easy, point-of-care method of monitoring and verifying smoking cessation efforts. |
| 07/22/2003 | | | | Nymox Brings Unique Approach to Alzheimer's Disease
topic: R&D: Alzheimer's Disease Treatments
July 22, 2003: Nymox Pharmaceutical Corporation is pursuing a three-pronged strategy against Alzheimer's disease (AD) that targets the prevention, diagnosis and treatment of AD according to Dr. Michael Munzar, the Company's Medical Director. |
| 07/17/2003 | | | | Antimicrobial Products Needed to Combat E. Coli Contamination
topic: R&D: E coli and Other Antibacterial Treatments
July 17, 2003: A recent U.S. government report on strategies for enhancing food safety has outlined the ongoing problems posed by E. coli O157 contamination of meat products and new initiatives to encourage the use of new technology such as antimicrobial agents, including new rules to provide food processors with much more flexibility in using antimicrobial agents in their products. Nymox Pharmaceutical Corporation recently announced plans to extend its field trials of NXC-4720, a novel antibacterial product under development for the treatment of E. coli O157:H7 meat contamination. |
| 07/15/2003 | | | | Recent Studies Support Potential for Statin Drug Use in Alzheimer's Disease
topic: Statins and Alzheimer's Disease
July 15, 2003: The results from a number of recent studies have shown that stain drugs have important potential for treatment and prevention of Alzheimer's disease (AD). The potential of statin use for AD has also attracted significant media attention, such as the cover story of the July 18, 2003 Newsweek Magazine. Nymox holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of AD. |
|